medical decision support medical decision support
Sign In

Hepatitis C Virus and HIV | Risk Factors for Hepatic Decompensation During Interferon-Ribavirin Therapy

Purpose: To identify risk factors for hepatic decompensation in a patient coinfected with HIV and HCV who is being treated with interferon-ribavirin.

Description

Bani-Sadr et al evaluated patients coinfected with HIV and hepatitis C virus (HCV) who had hepatic decompensation during interferon-ribavirin therapy. They identified risk factors which can help avoid this serious complication. The authors are from multiple hospitals in France.


 

Patient selection: coinfected with HIV and HCV and being treated with interferon-ribavirin

 

Outcome: hepatic decompensation

 

Risk factors for the hepatic decompensation:

(1) cirrhosis (a contraindication to interferon-ribavirin therapy because of the risk of hepatic decompensation)

(2) elevated serum total bilirubin

(3) therapy with didanosine

 

The odds ratio (OR) for each risk factor is in the order of 8 to 9.

 

The risk of hepatic decompensation increases with the number of risk factors present. To avoid hepatic decompensation then the number of risk factors must be kept to a minimum.

 


To read more or access our algorithms and calculators, please log in or register.

Specialty

Objective

ICD-10